In vivo assay of folate receptors in nonfunctional pituitary adenomas with99mTc-Folate SPECT/CT

Journal of Nuclear Medicine

Volumn 51, Issue 11, 2010, Pages 1716-1723

  Galt, James R ^a   Halkar, Raghuveer K ^a   Evans, Chheng Orn ^b   Osman, Naema A ^b   LaBorde, David ^b   Fox, Timothy H ^b   Faraj, Bajat A ^a   Kumar, Kush ^a   Wang, Houping ^b   Oyesiku, Nelson M ^b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Folate receptor; Pituitary adenoma; SPECT CT

Indexed keywords

FOLATE RECEPTOR; FOLATESCAN; FOLIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ARTIFACT; BRAIN; CANCER SURGERY; CHOROID PLEXUS; DIAGNOSTIC ACCURACY; DRUG UPTAKE; FEMALE; HUMAN; HYPOPHYSIS ADENOMA; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; NECK; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSSPHENOIDAL HYPOPHYSECTOMY; WESTERN BLOTTING; WHOLE BODY IMAGING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; HUMANS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; PITUITARY NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79851482173     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.061689     Document Type: Article

References (40)

1. Greenman Y, Melmed S. Diagnosis and management of nonfunctioning pituitary tumors. Annu Rev Med. 1996;47:95-106. (Pubitemid 26138875)
2. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101:613-619.
3. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769-4775. (Pubitemid 44917305)
4. Losa M, Mortini P, Barzaghi R, et al. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg. 2008;108:525-532. (Pubitemid 351357985)
5. Evans CO, Reddy P, Brat DJ, et al. Differential expression of folate receptor in pituitary adenomas. Cancer Res. 2003;63:4218-4224. (Pubitemid 36917949)
6. Evans CO, Young AN, Brown MR, et al. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab. 2001;86:3097-3107. (Pubitemid 32673472)
7. Antony AC. The biological chemistry of folate receptors. Blood. 1992;79:2807-2820.
8. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines: physiologic and clinical implications. Cancer. 1994;73:2432-2443. (Pubitemid 24129130)
9. Moreno CS, Evans CO, Zhan X, Okor M, Desiderio DM, Oyesiku NM. Novel molecular signaling and classification of human clinically nonfunctioning pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res. 2005;65:10214-10222. (Pubitemid 41743713)
10. Evans CO, Yao C, Laborde D, Oyesiku NM. Folate receptor expression in pituitary adenomas cellular and molecular analysis. Vitam Horm. 2008;79:235-266.
11. Yao C, Evans CO, Stevens VL, Owens TR, Oyesiku NM. Folate receptor alpha regulates cell proliferation in mouse gonadotroph alphaT3-1 cells. Exp Cell Res. 2009;315:3125-3132.
12. 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med. 2003;44:700-707.
13. 99mTc-EC20 for imaging folate receptor-positive tumors. J Nucl Med. 2004;45:857-866.
14. 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med. 2008;49:899-906.
15. 99mTc-based radiopharmaceutical. Bioconjug Chem. 2002;13:1200-1210.
16. Shimon I, Melmed S. Management of pituitary tumors. Ann Intern Med. 1998;129:472-483. (Pubitemid 28428084)
17. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev. 2004;56:1127-1141. (Pubitemid 38496512)
18. Lu Y, Sega E, Leamon CP, Low PS. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv Drug Deliv Rev. 2004;56:1161-1176. (Pubitemid 38496513)
19. Low PS, Antony AC. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev. 2004;56:1055-1058. (Pubitemid 38496506)
20. 188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors. Nucl Med Biol. 2007;34:595-601.
21. Ke CY, Mathias CJ, Green MA. The folate receptor as a molecular target for tumor-selective radionuclide delivery. Nucl Med Biol. 2003;30:811-817. (Pubitemid 38040989)
22. Ke CY, Mathias CJ, Green MA. Folate-receptor-targeted radionuclide imaging agents. Adv Drug Deliv Rev. 2004;56:1143-1160. (Pubitemid 38499700)
23. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci. 2005;94:2135-2146. (Pubitemid 41665275)
24. Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, Green MA. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med. 1996;37:1003-1008. (Pubitemid 126447142)
25. Wang S, Luo J, Lantrip DA, et al. Design and synthesis of [111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjug Chem. 1997;8:673-679.
26. Mathias CJ, Wang S, Waters DJ, Turek JJ, Low PS, Green MA. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J Nucl Med. 1998;39:1579-1585.
27. Guo W, Hinkle GH, Lee RJ. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. J Nucl Med. 1999;40:1563-1569. (Pubitemid 29428942)
28. 99mTc-ethylenedicysteine- folate: a new tumor imaging agent - synthesis, labeling and evaluation in animals. Cancer Biother Radiopharm. 1998;13:427-435.
29. 99mTc]DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical. Bioconjug Chem. 2000;11:253-257.
30. 99mTc(CO)(3)-DTPA-folate as a folate-receptor-targeted radiopharmaceutical. Nucl Med Biol. 2002;29:569-573.
31. 99mTc(CO)3-folates. Bioconjug Chem. 2006;17:797-806.
32. Müller C, Forrer F, Schibli R, Krenning EP, de Jong M. SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTcradiofolate. J Nucl Med. 2008;49:310-317. (Pubitemid 351225671)
33. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992;52:3396-3401.
34. Rosenthal MS, Cullom J, Hawkins W, Moore SC, Tsui BM, Yester M. Quantitative SPECT imaging: a review and recommendations by the Focus Committee of the Society of Nuclear Medicine Computer and Instrumentation Council. J Nucl Med. 1995;36:1489-1513.
35. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39:904-911. (Pubitemid 28216748)
36. Du Y, Tsui BM, Frey EC. Partial volume effect compensation for quantitative brain SPECT imaging. IEEE Trans Med Imaging. 2005;24:969-976. (Pubitemid 41178498)
37. David R, Koulibaly M, Benoit M, et al. Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases: a SPECT study with partial volume effect correction. Clin Neurol Neurosurg. 2008;110:19-24. (Pubitemid 350266163)
38. Willowson K, Bailey DL, Baldock C. Quantitative SPECT reconstruction using CT-derived corrections. Phys Med Biol. 2008;53:3099-3112. (Pubitemid 351892389)
39. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009;13:256-262.
40. Leamon CP, Jackman AL. Exploitation of the folate receptor in the management of cancer and inflammatory disease. Vitam Horm. 2008;79:203-233.